Evidence-based complementary and alternative medicine : eCAM. 2018;2018:7271509
Plain language summary
Edible mushrooms strengthen the immune system and are considered biological response modifiers (BRMs). This article reviews the research behind the use of mushroom compounds in cancer therapy. Beta-glucans from the cell walls of mushrooms are the major polysaccharide fraction that is responsible for immune modulating effects, through a number of mechanisms which are explored in this review article. Other important components include other polysaccharides, polysaccharide-protein complexes, agaritine, ergosterol, selenium, polyphenols, and terpenoids. Anti-cancer effects are mediated by stimulating lymphocytes, NK cells, and macrophages (all three specific immune cells), enhancing production of cytokines (immune messengers), inhibiting proliferation of cancer cells, promoting apoptosis (programmed cell death), and blocking angiogenesis (the development of blood vessels that feed the tumour), in addition to being cytotoxic to cancer cells. Medicinal mushrooms from which these compounds are derived and which have been researched for the treatment of various cancers include Ganoderma lucidum, G. tsugae, Schizophyllum commune, Sparassis crispa, Pleurotus tuberregium, P. rhinoceros, Trametes robiniophila Murill, Coriolus versicolor, Lentinus edodes, Grifola frondosa, and Flammulina velutipes, among others. Cancers in which benefits from medicinal mushrooms have been reported include breast, colorectal, cervical, skin, liver, ovarian, bladder, prostate, gastric, skin, lung, leukaemia, and stomach cancers.